The estimated Net Worth of Robert Crotty is at least 296 千$ dollars as of 19 August 2020. Mr. Crotty owns over 11,250 units of Nabriva Therapeutics Plc stock worth over 296,310$ and over the last 7 years he sold NBRV stock worth over 0$. In addition, he makes 0$ as General Counsel、 Secretary at Nabriva Therapeutics Plc.
Sign up
Mr. Crotty NBRV stock SEC Form 4 insiders trading
Robert has made over 3 trades of the Nabriva Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 11,250 units of NBRV stock worth 15,975$ on 19 August 2020.
The largest trade he's ever made was exercising 11,250 units of Nabriva Therapeutics Plc stock on 19 August 2020 worth over 15,975$. On average, Robert trades about 1,048 units every 26 days since 2018. As of 19 August 2020 he still owns at least 208,669 units of Nabriva Therapeutics Plc stock.
You can see the complete history of Mr. Crotty stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Crotty biography
Robert L. Crotty J.D. serves as General Counsel, Secretary of the Company. Mr. Crotty joined Nabriva Austria as general counsel and secretary prior to the Redomiciliation on June 14, 2017. Previously, Mr. Crotty served as vice president, general counsel, chief compliance officer and secretary of Vernalis Therapeutics, Inc. from January 2016 to June 2017. Prior to joining Vernalis, Mr. Crotty held several positions at Dendreon Corporation from April 2012 to July 2015, including president, general counsel and secretary from February 2015 to July 2015, executive vice president, general counsel and secretary from March 2014 to February 2015, and vice president, assistant general counsel and assistant secretary from April 2012 to February 2014. Before Dendreon, Mr. Crotty was senior counsel at NPS Pharmaceuticals from 2009 until 2012 and at ImClone Systems, Inc. from 2006 to 2009. Prior to going in-house, Mr. Crotty was an associate at Morgan, Lewis & Bockius and Norton Rose Fulbright. Mr. Crotty received his B.A. from Princeton University and J.D. from University of Pennsylvania.
How old is Robert Crotty?
Robert Crotty is 46, he's been the General Counsel、 Secretary of Nabriva Therapeutics Plc since 2017. There are 16 older and 1 younger executives at Nabriva Therapeutics Plc. The oldest executive at Nabriva Therapeutics Plc is George Talbot, 72, who is the Independent member of the Supervisory Board.
What's Robert Crotty's mailing address?
Robert's mailing address filed with the SEC is 414 COMMERCE DR., SUITE 120, FORT WASHINGTON, PA, 19034.
Insiders trading at Nabriva Therapeutics Plc
Over the last 8 years, insiders at Nabriva Therapeutics Plc have traded over 3,221,169$ worth of Nabriva Therapeutics Plc stock and bought 436,925 units worth 1,215,585$ . The most active insiders traders include Capital Viii, Llc Vivo、Bioventures Cayman Ltd Hbm、Charles A Jr Rowland. On average, Nabriva Therapeutics Plc executives and independent directors trade stock every 33 days with the average trade being worth of 23,562$. The most recent stock trade was executed by Daniel D Burgess on 2 August 2022, trading 11,341 units of NBRV stock currently worth 2,155$.
What does Nabriva Therapeutics Plc do?
nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo
What does Nabriva Therapeutics Plc's logo look like?
Complete history of Mr. Crotty stock trades at Nabriva Therapeutics Plc
Nabriva Therapeutics Plc executives and stock owners
Nabriva Therapeutics Plc executives and other stock owners filed with the SEC include:
-
Colin Broom,
Director -
Theodore Schroeder,
Chief Executive Officer, Director -
Steven Gelone,
President, Chief Operating Officer -
Francesco Lavino,
Chief Commercial Officer -
Gary Sender,
Chief Financial Officer -
Jennifer Schranz,
Chief Medical Officer -
Theodore R. Schroeder,
CEO & Director -
Dr. Steven P. Gelone Pharm. D,
Pres, COO & Director -
Dr. Colin Broom M.D.,
Director -
Stephen Webster,
Independent Member of the Supervisory Board -
George Talbot,
Independent member of the Supervisory Board -
Charles Rowland,
Independent Member of the Supervisory Board -
Carrie Bourdow,
Independent Member of the Supervisory Board -
Robert Crotty,
General Counsel, Secretary -
Daniel Burgess,
Independent Chairman of the Supervisory Board -
Werner Heilmayer,
VP of CMC & IP -
Dr. Christine J. Guico-Pabia M.B.A., M.D., M.P.H.,
Chief Medical Officer -
Gary L. Sender,
Consultant -
Jodi VanDerveer,
Sr. VP & Head of HR -
J. Christopher Naftzger BA, Esq., J.D.,
Gen. Counsel -
Daniel Dolan,
Chief Financial Officer -
Bioventures Cayman Ltd Hbm,
10% owner -
Elyse G. Seltzer,
Chief Medical Officer -
J. Christopher Naftzger,
General Counsel and Corp Sec -
Capital Viii, Llc Vivo,
10% owner -
Mark Corrigan,
Director -
Christine J. Guico Pabia,
Chief Medical Officer -
Daniel Dolan,
Chief Financial Officer -
Lisa Dalton,
Director